Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.51 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.49 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.49 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | CRHBP | P24387 | 1/20 | 0.47 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6449845 | 0.82 | TMPRSS4 (0.55) | GLAHPGDGAAKDM4EPOLB | |
| SCHEMBL18668519 | 0.77 | ALDH1A1 (0.57) | GLAHPGDGAAKDM4EPOLB | |
| SCHEMBL17111063 | 0.75 | ALDH1A1 (0.56) | GLAHPGDGAAKDM4EALDH1A1 | |
| SCHEMBL18668549 | 0.74 | ALDH1A1 (0.62) | GLAHPGDGAAPOLBALDH1A1 | |
| SCHEMBL15929894 | 0.72 | HTT (0.58) | GLAHPGDKDM4EALDH1A1MEN1 | |
| SCHEMBL707320 | 0.72 | ALDH1A1 (0.63) | GLAHPGDGAAKDM4EALDH1A1 | |
| SCHEMBL7827542 | 0.72 | GAA (0.77) | GLAHPGDGAAKDM4EPOLB | |
| SCHEMBL27515324 | 0.72 | GLA (0.58) | GLAHPGDGAAKDM4EPOLB | |
| SCHEMBL19976665 | 0.72 | GLA (0.52) | GLAHPGDGAAKDM4EPOLB | |
| SCHEMBL16761935 | 0.72 | PTGS1 (0.58) | GLAHPGDGAAALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | HAVCR2, HCCS, LIPC | GLA 2259/4885HPGD 258/4885GAA 519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.